Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient ...

Retrieved on: 2024-01-05 20:08:03

Tags for this article:

Click the tags to see associated articles and topics

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient .... View article details on hiswai:

Excerpt

Kiromic BioPharma, Inc. reported favorable safety and tolerability from the first patient 23 days after Deltacel? infusion in the Phase 1 clinical ...

Article found on: www.marketscreener.com

View Original Article